CureCancer at the Institute Molecular Medicine & Biomedical Research (IMBE)
CureCancer had the great honor to be invited and present its project, as an innovative startup, at the PANHELLENIC CONFERENCE, JUNE 30 – JULY 02, 2022, ATHENS, CROWNE PLAZA, under the auspices of the National and Kapodistrian University of Athens
The INSTITUTE OF MOLECULAR MEDICINE & BIOMEDICAL RESEARCH (IMBE) focuses its activities on biomedical research and education, as well as on the interconnection of the generated scientific knowledge with society.
As part of its events, it organizes a Panhellenic Conference on "Molecular Medicine from the Laboratory to Practice. Challenges and Questions". This year's conference emphasized research since it is at the forefront of innovative drug discovery. CureCancer was invited to present its work as an example of Innovation.
How CureCancer was born
For years we have been accepting people in treatment or with a history of cancer at the clinic. We found that, very often, people didn't know what medicines they were taking to help us relate their symptoms to those medicines so we could give them the right treatment. At the same time, telephone communication with their doctor had no effect, because he did not remember the medication. We therefore faced difficulties in accessing patients' medical history, which limited the provision of supportive care. Based on these difficulties, CureCancer was born.
CureCancer is supported
CureCancer is supported by the Athens Startup Incubator - THEA of the Entrepreneurship Development Center of the Athens Chamber of Commerce and Industry - EBEA and the Business Accelerator of the "Archimedes" Innovation and Entrepreneurship Center of the National and Kapodistrian University of Athens EKPA.
After evaluation, CureCancer was included in the Elevate Greece National Startup Registry, an initiative of the Greek Government, which aims to map startups and support them, with the ultimate goal of highlighting a strong innovation ecosystem.
CureCancer in the innovative SymbIASIS program
CureCancer has been selected to participate in the innovative SymbIASIS program of the European Institute of Innovation and Technology (EIT) Health, which is implemented in Greece by the National Center for Documentation and Electronic Content (EKT) and the Archimedes Center for Innovation and Entrepreneurship of the EKPA. The purpose of the program is to connect startups with Hospitals.
CureCancer has the great honor and the good fortune to connect with the Oncology Clinic of the ATTIKON Hospital, and Professor Ms. Amanda Psyrri, and expects to connect with the Oncology Clinics in two more Hospitals.
What CureCancer offers
CureCancer is a patient-centric platform, operated by the cancer patient himself. It offers holistic supportive care and cancer prevention to patients and their families. Patients organize their medical records, record their symptoms themselves, in real time, and contact their doctor with one click.
Timely reporting of symptoms by the patient himself will lead to early diagnosis and successful and effective treatment. In addition, the data recorded by the patient will help to evaluate the social, work and economic problems after the diagnosis of cancer and to more accurately draw up the Health policy.
At CureCancer, visitors can find a list of Health professionals and high-quality health products they need.
What are the benefits of CureCancer
Implementation of CureCancer can reduce the costs of cancer care, such as (a) the direct cost of cancer treatment toxicity, (b) the indirect cost of supportive care, and (c) the additional cost of inappropriate polypharmacy due to of insufficient communication between doctors. CureCancer offers Telemedicine to solve the problem of communication between doctors, who live in the city where the patient lives, i.e. outside the Oncology Center.
With CureCancer, treatment delays, outpatient clinic overload, travel, emergency hospital admissions and risk of infection are further reduced.
By regularly using the CureCancer platform, patients maintain their quality of life, save time and money, and live better and longer.
Professor Mosialos' comments about CureCancer
Professor Mossialos, commenting on the results of the CureCancer study, which was carried out in collaboration with the Society of Oncological Pathologists of Greece EOPE, emphasized the large number of doctors and other health professionals who need to monitor the patient during and after treatment